T. Rowe Price Investment Management Inc. lowered its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 44.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 796,986 shares of the biopharmaceutical company's stock after selling 640,845 shares during the period. T. Rowe Price Investment Management Inc. owned about 1.04% of Xenon Pharmaceuticals worth $26,739,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the business. GF Fund Management CO. LTD. raised its stake in shares of Xenon Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,952 shares of the biopharmaceutical company's stock valued at $65,000 after acquiring an additional 351 shares during the last quarter. Natixis Advisors LLC raised its stake in shares of Xenon Pharmaceuticals by 1.9% during the first quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company's stock valued at $806,000 after acquiring an additional 456 shares during the last quarter. Occudo Quantitative Strategies LP raised its stake in shares of Xenon Pharmaceuticals by 5.8% during the fourth quarter. Occudo Quantitative Strategies LP now owns 11,441 shares of the biopharmaceutical company's stock valued at $448,000 after acquiring an additional 630 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Xenon Pharmaceuticals by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock worth $2,726,000 after buying an additional 720 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Xenon Pharmaceuticals during the first quarter worth $30,000. Institutional investors own 95.45% of the company's stock.
Xenon Pharmaceuticals Stock Up 0.6%
NASDAQ:XENE traded up $0.22 during mid-day trading on Wednesday, hitting $38.87. 407,733 shares of the stock traded hands, compared to its average volume of 890,313. The business's 50-day moving average price is $33.42 and its 200 day moving average price is $33.93. The company has a market cap of $3.00 billion, a PE ratio of -10.95 and a beta of 1.16. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same quarter in the prior year, the firm earned ($0.75) EPS. Analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have commented on XENE shares. HC Wainwright restated a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday, May 5th. Wall Street Zen lowered shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Wedbush lifted their price objective on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 12th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, August 12th. Eleven equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Xenon Pharmaceuticals has an average rating of "Buy" and an average price target of $53.20.
Check Out Our Latest Stock Analysis on Xenon Pharmaceuticals
Xenon Pharmaceuticals Company Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Articles
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access